All lentiviral vectors articles
-
NewsScottish biotech company Lentitek secures £1m funding to advance next generation cancer treatments
Biotech company Lentitek Ltd has secured £700,000 in private funding from Equity Gap, bringing its total investment to £1 million in the last six months. It develops manufacturing technologies for lentiviral vectors, used with CAR-T cell and gene therapies.